Selective NaV1.8 Inhibition for Pain Management: Current Evidence and Future Potential of Suzetrigine.

purpose of reviewPain is a complex sensory and emotional experience influenced by biological, psychological, and social factors. While NSAIDs, opioids, anticonvulsants, and antidepressants are frequently used for analgesia, these conventional therapies often fail to provide adequate pain relief for many patients. Moreover, their use is limited by safety concerns and adverse effects, thus emphasizing the need for more targeted non-opioid alternatives. Voltage-gated sodium channel NaV1.8 has emerged as a compelling therapeutic target due to its expression in peripheral nociceptors and its critical role in action potential propagation during inflammatory and neuropathic pain conditions. RECENT

findingsWhile early drug development efforts were limited by challenges with selectivity and toxicity, technological advancements within the field of pharmacology have enabled the creation of highly selective small-molecule inhibitors. Suzetrigine, approved by the FDA in 2025, is the first highly selective, orally administered NaV1.8 inhibitor, demonstrating potent inhibition of nociceptive signaling without central nervous system (CNS) or cardiac effects. Recent phase 3 trials indicate that suzetrigine provides clinically significant analgesia for moderate to severe acute postoperative pain, with efficacy comparable to opioid therapy but without the risks of respiratory depression, sedation, or dependence. Suzetrigine represents a novel, non-opioid approach to pain management by selectively targeting peripheral nociceptive signaling. This review summarizes the physiological basis of pain, limitations of current analgesics, the rationale for targeting NaV1.8, and the pharmacology, clinical evidence, and emerging therapeutic potential of suzetrigine. Further studies on the use of suzetrigine in chronic neuropathic pain conditions are warranted.